A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Epcoritamab (Primary) ; Lenalidomide; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms EpLCART
Most Recent Events
- 05 Jun 2025 Minimum age is reduced from 18 years to 16 years, due to which the study will now be enrolling subjects from adolescent age group also.
- 12 Aug 2024 Status changed from not yet recruiting to recruiting.
- 21 May 2024 New trial record